11
total announcements
524518.BO · 15 min delayed
Krebs Biochemicals & Industries Ltd-$
Krebs Biochemicals & Industries Ltd has submitted certificates under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, confirming the details of securities dematerialized/rematerialized during the period.
Krebs Biochemicals & Industries Ltd-$
Krebs Biochemicals & Industries Ltd has announced the voting results of its 34th Annual General Meeting (AGM), with all five resolutions passed by the requisite majority. The company had appointed a scrutinizer to conduct the e-voting process, which was open from September 25 to 28, 2026.
Krebs Biochemicals & Industries Ltd-$
Krebs Biochemicals & Industries Ltd held its 34th Annual General Meeting (AGM) on September 29, 2026, through video conferencing. The meeting was attended by all directors, including the chairman, and representatives of statutory auditors, secretarial auditors, and a scrutinizer. The company provided electronic voting facility to members, and the e-voting process was carried out between September 25-28, 2026. The meeting approved the audited financial statements, re-appointed directors, and ratified the remuneration payable to cost auditors. The results of the voting will be declared after the report of the scrutinizer is received.
Krebs Biochemicals & Industries Ltd-$
Krebs Biochemicals & Industries Ltd has announced the notice of its 34th Annual General Meeting (AGM) to be held on September 29, 2026, through video conferencing. The company has also provided e-voting facility to its members to exercise their right to vote on the agenda items.
Krebs Biochemicals & Industries Ltd-$
Krebs Biochemicals & Industries Ltd has announced its 34th Annual Report for the financial year ended 31st March 2026, which includes the company's financial performance, corporate governance, and related party transactions.
Krebs Biochemicals & Industries Ltd-$
Krebs Biochemicals & Industries Ltd has announced the prior intimation of its 34th Annual General Meeting (AGM) through a newspaper advertisement, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Krebs Biochemicals & Industries Ltd-$
Krebs Biochemicals & Industries Ltd has published unaudited financial results for the quarter ended 30.06.2026, showing a net profit of Rs. 248.48 lakhs and a total comprehensive income of Rs. 248.48 lakhs.
Krebs Biochemicals & Industries Ltd-$
Krebs Biochemicals & Industries Ltd has announced its unaudited financial results for the 1st quarter ended June 30, 2026, with the Board of Directors approving and taking on record the results and a limited review report by the auditors.
Krebs Biochemicals & Industries Ltd-$
Krebs Biochemicals & Industries Ltd has announced the outcome of its board meeting, where the board approved and took on record the unaudited financial results for the 1st quarter ended June 30, 2026, and the limited review report by the auditors on the unaudited financial results.
Krebs Biochemicals & Industries Ltd-$
Krebs Biochemicals & Industries Ltd has scheduled a Board Meeting on August 6, 2026, to consider and adopt the unaudited financial results for the 1st quarter ended June 30, 2026.
Krebs Biochemicals & Industries Ltd-$
Krebs Biochemicals & Industries Ltd announced the closure of its trading window for dealing in company securities, effective from the close of business hours on June 30, 2026. This closure will remain in effect until 48 hours after the declaration of the unaudited financial results for the first quarter ended June 30, 2026. This measure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and applies to promoters, directors, designated persons, and their immediate relatives.